Seattle Genetics (SGEN) Misses Q4 EPS by 32c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus

Go back to Seattle Genetics (SGEN) Misses Q4 EPS by 32c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus

Seattle Genetics (SGEN) PT Lowered to $64 at Piper Jaffray

February 8, 2019 8:52 AM EST

Piper Jaffray analyst Joseph Catanzaro lowered the price target on Seattle Genetics (NASDAQ: SGEN) to $64.00 (from $66.00) while maintaining a Neutral rating.

... More